0001209191-21-044119.txt : 20210630
0001209191-21-044119.hdr.sgml : 20210630
20210630191130
ACCESSION NUMBER: 0001209191-21-044119
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210630
FILED AS OF DATE: 20210630
DATE AS OF CHANGE: 20210630
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Manning Paul B
CENTRAL INDEX KEY: 0001494695
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40551
FILM NUMBER: 211063408
MAIL ADDRESS:
STREET 1: 200 GARRETT STREET SUITE S
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001576885
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364108129
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
BUSINESS PHONE: 925-368-8508
MAIL ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-06-30
0
0001576885
Acumen Pharmaceuticals, Inc.
ABOS
0001494695
Manning Paul B
C/O ACUMEN PHARMACEUTICALS, INC.
427 PARK STREET
CHARLOTTESVILLE
VA
22902
0
0
1
0
Common Stock
89709
I
See Footnotes
Series A-1 Preferred Stock
Common Stock
1634515
I
See Footnote
Series B Preferred Stock
Common Stock
1315969
I
See Footnote
Series B Preferred Stock
Common Stock
657985
I
See Footnote
The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock
have no expiration date.
The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Katherine Denby, Attorney-in-Fact
2021-06-30
EX-24.3_996480
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Katherine Denby, Katie Lapidus, Jill Simon and Steven Renftle
of Cooley LLP, and Daniel Joseph O'Connell of Acumen Pharmaceuticals, Inc. (the
"Company"), signing individually, the undersigned's true and lawful attorneys-in
fact and agents to:
(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") Form ID and
Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in
connection therewith) in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder
in the undersigned's capacity as an officer, director or beneficial owner of
more than 10% of a registered class of securities of the Company;
(2) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Forms 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and
(3) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company or Cooley LLP, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: May 26, 2021
/s/ Paul B. Manning
Paul B. Manning